PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
PVCT$0.04-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
| For the Three Months Ended · For the Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | September 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| Net Loss | $(1,273,710) | $(1,323,629) | $(3,563,375) | $(4,337,312) |
| Other Comprehensive Income: | ||||
| Foreign currency translation adjustments | 168 | 34 | 556 | 414 |
| Comprehensive Loss, net | (1,273,542) | (1,323,595) | (3,562,819) | (4,336,898) |
| Comprehensive Loss attributable to non-controlling interest | (7,434) | (12,348) | (24,079) | (71,503) |
| Comprehensive Loss attributable to controlling interest | $(1,266,108) | $(1,311,247) | $(3,538,740) | $(4,265,395) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.